No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Avacta Therapeutics said on Wednesday it had appointed healthcare executive Patrick Vink to its board as non-executive deputy chairman and senior independent director.
Vink is currently chairman of Arch Biopartners, Micreos Group, Secura Bio and F2G, and sits on the board of Spero Therapeutics.
Chief executive Christina Coughlin said Vink brought "considerable sector experience in Pharma partnering, financing, and operations" as Avacta advances its preCISION oncology platform and continues partnership discussions.
Vink said upcoming data, including first clinical results from AVA6103, "could be transformative for Avacta."
At 1202 BST, shares in Avacta Group were down 1.68% at 69.53p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.